Arrivent Biopharma, Inc.
Clinical trials sponsored by Arrivent Biopharma, Inc., explained in plain language.
-
Global race for better lung cancer treatment targets rare mutations
Disease control Recruiting nowThis global Phase 3 trial is comparing a new drug called firmonertinib against two existing standard treatments for people with advanced non-small cell lung cancer that has specific, less common EGFR genetic mutations. The study aims to see if firmonertinib can better control the…
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New cancer drug MRG007 enters human testing for Tough-to-Treat tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called MRG007 in people with advanced solid tumors that have spread and cannot be surgically removed. The main goals are to find a safe dose and see if the drug helps shrink tumors in patients with colorectal, gastric, pancreatic, and …
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC